Gee there is some heavy duty science going on here.
The most interesting part of the conversation (with the good professor) was his incredulity over why the 2 existing approved products for multiple myeloma use the 41BB co-stimulatory domain when his research has shown that the CD28 domain (which is included in ALA101) is far, far more effective.
Good news indeed that hasn't been picked up by the market I think.
Ann: CAR-iNKT Cell Platform Data Presented at ASH, page-5
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.005(4.17%) |
Mkt cap ! $131.2M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 11.5¢ | $136.1K | 1.130M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 79098 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 156038 | 6 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.5¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 12.3¢ | 12.5¢ | 11.8¢ | 748911 | ||
| Last updated 15.48pm 13/05/2024 ? | |||||
| ALA (ASX) Chart |